Oesophageal cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Oesophageal cancer metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-drug-combination-for-patients-with-advanced-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-cancer/ Wed, 29 Apr 2026 15:04:42 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-drug-combination-for-patients-with-advanced-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-cancer/ This clinical trial is focused on studying treatments for HER2-positive gastric or gastroesophageal junction cancer, which is a type of cancer that affects the stomach and the area where the stomach meets the esophagus. The study will explore the effectiveness of a new treatment combination involving Trastuzumab Deruxtecan (also known as Enhertu®) along with chemotherapy, with or without the addition of Pembrolizumab. The trial will compare this new combination to the current standard treatment, which includes chemotherapy and Trastuzumab, with or without Pembrolizumab.

The purpose of the study is to determine how well these treatments work in patients who have not received prior treatment for their advanced cancer. Participants will receive their treatment through an intravenous injection, which means the medication is given directly into a vein. The study will last for a period of up to 60 weeks, during which participants will be monitored regularly to assess the progress of their cancer and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to evaluate the size and spread of the cancer. The trial aims to provide valuable information on the potential benefits of the new treatment combination, which could lead to improved outcomes for patients with this type of cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer https://clinicaltrials.eu/trial/study-of-hlx22-trastuzumab-and-chemotherapy-for-patients-with-advanced-or-metastatic-stomach-and-gastroesophageal-cancer/ Wed, 29 Apr 2026 15:04:37 +0000 https://clinicaltrials.eu/trial/study-of-hlx22-trastuzumab-and-chemotherapy-for-patients-with-advanced-or-metastatic-stomach-and-gastroesophageal-cancer/ This clinical trial is focused on studying treatments for locally advanced or metastatic gastroesophageal junction and gastric cancer. The study will explore the effectiveness of a new treatment combination involving HLX22, which is a recombinant humanized anti-HER2 monoclonal antibody injection. This treatment will be combined with trastuzumab and a type of chemotherapy known as XELOX. The study will compare this combination to the standard treatment of trastuzumab and XELOX, with or without the addition of pembrolizumab, which is a solution for infusion.

The purpose of the study is to evaluate how well the new combination works as a first-line treatment for patients with this type of cancer. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure the results are unbiased. The study will take place over a period of time, with regular assessments to monitor the progress and health of the participants.

Throughout the study, researchers will focus on key outcomes such as progression-free survival, which measures how long patients live without the cancer getting worse, and overall survival, which measures how long patients live overall. The study will also look at the safety of the treatments and any side effects that may occur. By the end of the study, the goal is to determine if the new treatment combination offers a better option for patients with this type of cancer.

]]> Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer https://clinicaltrials.eu/trial/study-of-domvanalimab-zimberelimab-and-chemotherapy-for-patients-with-advanced-esophageal-or-gastric-cancer/ Wed, 29 Apr 2026 15:00:02 +0000 https://clinicaltrials.eu/trial/study-of-domvanalimab-zimberelimab-and-chemotherapy-for-patients-with-advanced-esophageal-or-gastric-cancer/ This clinical trial is focused on studying treatments for people with certain types of cancer in the upper part of the digestive system, specifically gastric cancer, gastroesophageal junction cancer, and esophageal cancer. These cancers are either locally advanced, meaning they have grown but not spread to distant parts of the body, or metastatic, meaning they have spread to other areas. The study is testing a new combination of treatments that includes two experimental drugs, domvanalimab and zimberelimab, along with chemotherapy. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. This new combination will be compared to another treatment that uses the drug nivolumab with chemotherapy.

The purpose of the study is to see if the new combination of domvanalimab and zimberelimab with chemotherapy can help people live longer compared to the treatment with nivolumab and chemotherapy. Participants in the study will be randomly assigned to receive either the new combination treatment or the nivolumab treatment. The study will last for up to 24 months, during which participants will receive their assigned treatment and be monitored regularly by the study team. The study will also look at how the treatments affect the participants’ quality of life and any side effects they may experience.

In addition to the main goal of comparing how long participants live with each treatment, the study will also look at other important factors. These include how long it takes for the cancer to start growing again, how many participants experience a reduction in their cancer size, and how long these reductions last. The study will also monitor any side effects or adverse events that participants may experience during the trial. This information will help researchers understand the safety and effectiveness of the new treatment combination.

]]>